Obstet Gynecol:有多少女性禁忌激素避孕?

2021-04-10 Nebula MedSci原创

五位产后女性中就有一位禁忌激素避孕!

激素避孕是预防怀孕的有效方法,几乎适用于所有人。但是,有些人的健康状况可能会增加使用激素避孕药的不良事件风险。此外,有些人同时服用的药物可能会受到激素避孕药的影响或降低其疗效。

既往研究报告指出,普通人群中禁忌采用联合激素避孕的概率在2%~16%之间,但该概率在得克萨斯州育龄的拉丁裔女性研究中更高(39%)

本研究旨在了解产后女性禁忌采用激素避孕的概率。

研究人员从德克萨斯州的8家医院招募了计划产后推迟2年或更长时间再次生育的低收入产后妇女进行前瞻性队列研究。根据美国疾病控制和预防中心2016年避孕医疗资格标准,女性自我报告的健康状况与激素联合方法和仅使用黄体酮避孕的第3/4类禁忌症相对应。采用混合效应Poisson回归模型来评估与产后6个月内报告的任何禁忌症相关的特征。

有激素避孕禁忌症的概率

在完成了6个月访谈的1452名女性中,19.1%的人报告了联合激素避孕的第3/4类禁忌症(16.8%的是4类),5.4%的人报告了甲羟孕酮的禁忌症(0.1%的是4类)。只有0.8%的人对只服用黄体酮药片有3/4类禁忌症,0.6%的人对黄体酮植入物有禁忌症。

最常见的禁忌症有先兆偏头痛(12.4%)和高血压(4.8%)。年龄在30岁以上(发生率1.45,95%CI 1.21~1.73)、超重(1.39,1.07~1.80)、肥胖(1.55,1.16~2.07)、有医保(1.34,1.04~1.74)的女性的禁忌采用激素避孕的概率较高。与在美国出生的拉丁裔女性相比,黑人女性有激素避孕禁忌症的概率较高(概率 1.37,95%CI 1.14~1.64),而在外国出生的拉丁裔女性有激素避孕禁忌症的概率较低(0.71,95%CI 0.59~0.86)。

在有禁忌症的女性中,28名(10.3%)使用了联合激素避孕,6名(8%)使用了禁忌达到孕酮方法。

综上,近五分之一的受试者存在3/4类联合激素避孕的禁忌症。不良分娩结局风险较高的患者更有可能有采用激素避孕的禁忌症

原始出处:

Coleman-Minahan Kate,Ela Elizabeth J,White Kari et al. Contraindications to Hormonal Contraception Among Postpartum Women in Texas. Obstet Gynecol, 2021, https://doi.org/10.1097/AOG.0000000000004347

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044181, encodeId=fea52044181d1, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Nov 26 17:57:07 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011446, encodeId=d72720114464f, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Fri Sep 24 19:57:07 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956501, encodeId=6343956501ed, content=比较担心致癌的副作用,没有提及, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78f92247333, createdName=12159132m27(暂无昵称), createdTime=Tue Apr 13 11:10:20 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956481, encodeId=0e5f9564819a, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Apr 13 10:34:29 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545119, encodeId=2686154511988, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Apr 12 08:57:07 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955727, encodeId=0834955e274f, content=看, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d5479018, createdName=ms9000001550113929, createdTime=Sat Apr 10 18:21:26 CST 2021, time=2021-04-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044181, encodeId=fea52044181d1, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Nov 26 17:57:07 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011446, encodeId=d72720114464f, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Fri Sep 24 19:57:07 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956501, encodeId=6343956501ed, content=比较担心致癌的副作用,没有提及, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78f92247333, createdName=12159132m27(暂无昵称), createdTime=Tue Apr 13 11:10:20 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956481, encodeId=0e5f9564819a, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Apr 13 10:34:29 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545119, encodeId=2686154511988, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Apr 12 08:57:07 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955727, encodeId=0834955e274f, content=看, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d5479018, createdName=ms9000001550113929, createdTime=Sat Apr 10 18:21:26 CST 2021, time=2021-04-10, status=1, ipAttribution=)]
    2021-09-24 yhy100200
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044181, encodeId=fea52044181d1, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Nov 26 17:57:07 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011446, encodeId=d72720114464f, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Fri Sep 24 19:57:07 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956501, encodeId=6343956501ed, content=比较担心致癌的副作用,没有提及, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78f92247333, createdName=12159132m27(暂无昵称), createdTime=Tue Apr 13 11:10:20 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956481, encodeId=0e5f9564819a, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Apr 13 10:34:29 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545119, encodeId=2686154511988, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Apr 12 08:57:07 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955727, encodeId=0834955e274f, content=看, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d5479018, createdName=ms9000001550113929, createdTime=Sat Apr 10 18:21:26 CST 2021, time=2021-04-10, status=1, ipAttribution=)]
    2021-04-13 12159132m27(暂无昵称)

    比较担心致癌的副作用,没有提及

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2044181, encodeId=fea52044181d1, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Nov 26 17:57:07 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011446, encodeId=d72720114464f, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Fri Sep 24 19:57:07 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956501, encodeId=6343956501ed, content=比较担心致癌的副作用,没有提及, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78f92247333, createdName=12159132m27(暂无昵称), createdTime=Tue Apr 13 11:10:20 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956481, encodeId=0e5f9564819a, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Apr 13 10:34:29 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545119, encodeId=2686154511988, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Apr 12 08:57:07 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955727, encodeId=0834955e274f, content=看, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d5479018, createdName=ms9000001550113929, createdTime=Sat Apr 10 18:21:26 CST 2021, time=2021-04-10, status=1, ipAttribution=)]
    2021-04-13 易水河

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2044181, encodeId=fea52044181d1, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Nov 26 17:57:07 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011446, encodeId=d72720114464f, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Fri Sep 24 19:57:07 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956501, encodeId=6343956501ed, content=比较担心致癌的副作用,没有提及, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78f92247333, createdName=12159132m27(暂无昵称), createdTime=Tue Apr 13 11:10:20 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956481, encodeId=0e5f9564819a, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Apr 13 10:34:29 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545119, encodeId=2686154511988, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Apr 12 08:57:07 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955727, encodeId=0834955e274f, content=看, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d5479018, createdName=ms9000001550113929, createdTime=Sat Apr 10 18:21:26 CST 2021, time=2021-04-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2044181, encodeId=fea52044181d1, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Nov 26 17:57:07 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011446, encodeId=d72720114464f, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Fri Sep 24 19:57:07 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956501, encodeId=6343956501ed, content=比较担心致癌的副作用,没有提及, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78f92247333, createdName=12159132m27(暂无昵称), createdTime=Tue Apr 13 11:10:20 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956481, encodeId=0e5f9564819a, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Apr 13 10:34:29 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545119, encodeId=2686154511988, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Apr 12 08:57:07 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955727, encodeId=0834955e274f, content=看, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d5479018, createdName=ms9000001550113929, createdTime=Sat Apr 10 18:21:26 CST 2021, time=2021-04-10, status=1, ipAttribution=)]
    2021-04-10 ms9000001550113929

    0

相关资讯

Otolaryngol Head Neck Surg:怀孕、雌激素暴露和耳硬化症的发展:1196名妇女的病例对照研究

最近,有研究人员确定了妊娠史或双侧眼球切除术是否与随后的耳硬化症发展或疾病严重程度有关。

JCO:为什么乳腺癌的四种复发风险预测分析结果不一样?

Oncotype DX复发评分(RS)、芯片50(PAM50)复发风险(ROR)的Prosigna预测分析、EndoPredict (EP)和乳腺癌指数(BCI)常用于临床评估接受内分泌治疗的患者远处

Cell Death & Disease:抗雌激素药物Faslodex能够增加RCC患者对Sunitinib的敏感性

Sunitinib已经成为治疗转移透明细胞肾细胞癌(ccRCC)的主要药物,其能够抑制肿瘤的生长和血管生成。大多数的ccRCC肿瘤在产生Sunitinib抗性后会再生,但其详细的机制仍旧需要探索。

BMJ:激素替代治疗类型及持续时间相关的乳腺癌风险

不同激素替代治疗人群的乳腺癌风险不一致,近5年内长期应用雌激素治疗或雌激素-孕激素联合治疗人群需警惕乳腺癌风险

JAHA:美国研究称,更年期女性雌激素贴片增加心脏外的油

激素替代疗法是治疗更年期相关症状的常用疗法

Sci Rep:雌激素和选择性雌激素受体调节剂对前列腺细胞增殖影响的系统研究

雌激素信号途径能够通过雌激素受体α和β(ERα和ERβ)调节前列腺癌(PCa)的进展。选择性雌激素受体调制剂(SERMs)已经用于治疗乳腺癌,ERs也已经被